New Titanium Mesh Review Makes the Denominator Part of Device Evidence

A systematic review and proportional meta-analysis published on 2026-08-26 offers a useful caution for anyone reading clinical percentages about fabricated titanium devices. The authors evaluated titanium mesh and tray systems used with bone grafting for mandibular continuity reconstruction, but they first had to decide which reports represented independent cohorts, which denominator each outcome used and which follow-up records were eligible (full open-access review).

That work changes the buyer question. A pooled complication rate is not a property of “titanium mesh” in the abstract. It is an estimate constructed from particular devices, defects, surgical contexts, follow-up rules and denominator decisions.

The review had to build the evidence set before pooling it

The review followed PRISMA 2020 and was prospectively registered as PROSPERO CRD420261428392. After screening the literature, the authors identified 10 representative independent cohorts. Eight contributed to at least one primary pooled outcome. Other reports remained useful for qualitative interpretation or evidence mapping but were not counted again when patient populations overlapped or denominators could not be separated.

This is not administrative cleanup. If two papers describe some of the same patients, treating both as independent enlarges the apparent evidence base. If one study reports patients and another reports reconstruction sites, the units are not automatically interchangeable. If exposure is reported for one subgroup but infection for another, one total cohort size cannot safely serve every outcome.

The denominator therefore belongs to the causal story. It tells the reader who was actually at risk, for how long and under which reconstruction definition.

The pooled percentages are benchmarks with weak certainty

In the primary analyses, the pooled proportion was 8.8% for device exposure, 14.5% for infection, 5.3% for mechanical failure and 14.5% for unplanned reoperation or device removal. The paper rated the certainty of evidence very low for all four outcomes.

Those values are not product guarantees. The evidence base was dominated by small, non-randomized, single-arm clinical series with sparse events, heterogeneous reporting and geographically concentrated experience. Even an estimated heterogeneity of zero was interpreted cautiously because few cohorts and events can make between-study variation difficult to detect.

The correct use is exploratory benchmarking. A manufacturer or buyer can use the review to identify failure categories that deserve design and follow-up attention. It cannot use the pooled figures as a universal safety rate for a new mesh, a new patient population or a different clinical pathway.

Manufacturing route could not be isolated from clinical context

The review included preformed, stock, manually adapted, model-bent, cast, CAD/CAM-assisted and patient-specific designs. Only two representative cohorts used additively manufactured patient-specific systems. Their reporting covered uneven combinations of outcomes, so formal subgroup pooling and between-group inference were not appropriate.

That limit matters for suppliers of titanium mesh. Anatomical fit, contour planning and manufacturing precision may improve, but a better geometric match does not automatically prove lower exposure, infection or revision. Soft-tissue coverage, defect complexity, fixation, graft type, radiotherapy, surgical timing, follow-up and institutional experience can all sit between manufactured geometry and clinical outcome.

The manufacturing claim and the clinical claim must therefore remain separate:

• the material file establishes alloy identity, route, cleanliness and traceability;
• the manufacturing file establishes geometry, process control, finishing and inspection;
• the device file establishes design intent and application boundary;
• the clinical file establishes outcomes for a defined cohort and denominator.

A six-layer cohort-denominator-to-device map

This framework prevents two opposite errors. One is dismissing clinical evidence because certainty is low. The other is using a precise-looking percentage as though it transfers to every titanium device. The review is useful precisely because it shows what the current data can and cannot support.

The buyer value is disciplined separation

A titanium supplier does not control the entire clinical pathway, and a surgeon does not usually control the mill route. That division makes the evidence interfaces more important. Material certificates should map into the device history. Geometry and finishing records should map into design control. Clinical outcomes should remain attached to the cohort, indication and denominator that generated them.

This article also stays separate from our recent analysis of comparative cage evidence. That earlier framework ranked direct and indirect evidence across implant materials. The new review answers a different question: how cohort overlap and denominator construction can change the apparent complication benchmark before any material or manufacturing comparison is attempted.

The restrained conclusion is simple. The review identifies exposure, infection and unplanned intervention as important concerns, but it does not establish comparative superiority for additive manufacturing or any specific titanium mesh route. For buyers, the most useful request is not a headline percentage. It is the evidence table showing which device, which patients, which denominator, which endpoint and which follow-up produced that number.